Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

NCT07581912 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT07581912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07581912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Recruiting
Start date
April 30, 2026
Completion date
December 31, 2031
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cetuximab n01, colorectal cancer, fulzerasib, kras g12c mutant advanced solid tumors